IsomAb pockets £7.5M seed funding to spur development of arterial disease drug
20 Feb 2024
IsomAb is one step closer to bringing its peripheral artery disease (PAD) treatment to the clinic after closing a £7.5-million ($9.4 million) seed financing led by Broadview Ventures. Existing investor SCVC also participated in the round, as did MEIF Proof of Concept & Early Stage Fund, which is managed by Mercia Ventures and part of the Midlands Engine Investment Fund.
The company’s lead candidate, ISM-001, is a preclinical isoform-specific monoclonal antibody (mAb) in development to treat PAD in patients with concomitant metabolic syndrome and type 2 diabetes.
ISM-001 is designed to enhance the body’s natural workaround when a buildup of fats block blood vessels, limiting blood flow to tissues and causing heart attack or stroke.
The production of new blood vessels to bypass the clogged ones relies on a balance of two VEGF-A isoforms: VEGF-A165a and VEGF-A165b. If levels of the latter are too high, the body is unable to create new vessels.
ISM-001 inhibits VEGF-A165b to rebalance the two isoforms and promote blood vessel production.
"IsomAb offers a fresh approach to the treatment of vascular disease. Although the initial focus will be on treating diabetics, research shows high levels of VEGF-A165b are also linked to increased risk of heart attack and stroke in non-diabetics, so it could have much wider applications,” Mercia Ventures partner Hannah Tapsell Chapman said.
Tuesday’s round will fund IsomAb through a clinical trial authorisation submission to UK regulators.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.